TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12857764
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training program (6 months of physical therapy, strength training, and walking followed by 3 months of endurance exercise at 78% of peak heart rate)
Study: 2003858
Drug: Ketotifen (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (6 mg/day)
Study: 30342551
Drug: Guanxinjing capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanxinjing capsule (GXJ)
Study: 22507611
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of daily complementary feeding
Study: 19850529
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received pharmacotherapy (anticholinergics or desmopressin) as needed
Study: 16203877
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg orally per week for twenty‐five weeks)
Study: 16203877
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no medication or placebo)
Study: 8657762
Drug: gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel containing lysated keratinocyte cultures
Study: 8657762
Drug: placebo-gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo-gel
Study: 6093960
Drug: Ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 100 mg
Study: 6125203
Drug: Ranitidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 200 mg
Study: 6118248
Drug: Ranitidine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (various doses)
Study: 31335174
Drug: Traditional Occupational
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Occupational Therapy (TOT) intervention group
Study: 31104833
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (oral phosphate and active vitamin D)
Study: 17479609
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate
Study: 11185665
Drug: Fe2+ form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe2+ form of elemental iron, 7.5 mg daily
Study: 11185665
Drug: Nonionic trivalent
Normalized name: LANOLIN DERIVATES,NONIONIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic trivalent iron (FeIII) complexed with polysaccharides, 7.5 mg daily
Study: 9124858
Drug: CP following
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP following oral administration of diltiazem (60 mg)
Study: 9124858
Drug: CP following
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP following oral administration of nifedipine (20 mg)
Study: 3893511
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2 g of sulfametopyrazine
Study: 3893511
Drug: Ampicillin 250
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 250 mg thrice daily for 7 days
Study: 28419732
Drug: Retosiban (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retosiban (6 mg/h infusion for 24 hours, followed by 12 mg/h infusion over the next 24 hours; preceded by a 6 mg loading dose over 5 minutes)
Study: 24888381
Drug: Oral simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral simvastatin 40 mg at night for 12 months
Study: 19946776
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 1,200 mg and vitamin D3 400 IU (10 microg)
Study: 18665021
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate 160 mg IM
Study: 16037175
Drug: Lateral position
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral position (L group)
Study: 1835619
Drug: Sizofiran (SPG)
Normalized name: Sizofiran
DrugBank: Sizofiran (DB13128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sizofiran (SPG) administered with antitumour drugs
Study: 27628168
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity promotion intervention (exercise program of 1-hour sessions twice a week for a year)
Study: 23392270
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg simvastatin daily (high dose) over 3 weeks
Study: 23392270
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin daily (normal dose)
Study: 20674311
Drug: Resveratrol 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 30 mg
Study: 20674311
Drug: Resveratrol 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 90 mg
Study: 20674311
Drug: Resveratrol 270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 270 mg
Study: 21798991
Drug: One-day interval
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 17-28 hours)
Study: 21798991
Drug: Two-day interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 41-45 hours)
Study: 17702040
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (5,000 units, three times weekly subcutaneously)
Study: 12225327
Drug: Consensus interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consensus interferon (CIFN) induction therapy for one month followed by standard 9 microg of CIFN thrice weekly for 11 months
Study: 12225327
Drug: Rapid viral
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid viral response (RVR) during the first month of induction dosing
Study: 12225327
Drug: Induction dosing
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction dosing with CIFN
Study: 12225327
Drug: Early viral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early viral kinetics during the first month of therapy
Study: 15641227
Drug: Eradication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication treatment (Pantoprazole 40 mg 1x/day, Amoxycillin 1000 2x/day, Claritromycin 500 2x/day)
Study: 8787478
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (hyperventilation, inspired oxygen fraction of 0.80, and inotropic agents)
Study: 7440192
Drug: Heparin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (3 x 5000 IU/day)
Study: 7440192
Drug: Heparin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (2 x 5000 IU/day) + 0.5 mg dihydroergot (DHE)
Study: 21078382
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of arsenic
Study: 12195131
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times daily
Study: 9425508
Drug: Continuous risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous risedronate 2.5 mg
Study: 9425508
Drug: Cyclic risedronate
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic risedronate 2.5 mg
Study: 8345499
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg verapamil
Study: 8503714
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs simultaneously
Study: 3620826
Drug: Hexabrix (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexabrix (320 mg iodine/ml)
Study: 3620826
Drug: Iopamiron (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamiron (300 mg iodine/ml)
Study: 3620826
Drug: iohexol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol (300 mg iodine/ml)
Study: 27302000
Drug: Fractionated propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fractionated propofol administration (FPA)
Study: 12163917
Drug: Amodiaquine (AQ)
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine (AQ) - 30 mg/kg body weight in three divided daily doses
Study: 12163917
Drug: Sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP) - 25 mg/kg body weight of sulfadoxine and 1.25 mg/kg of pyrimethamine in a single oral dose
Study: 12163917
Drug: Sulfadoxine-pyrimethamine-amodiaquine combination
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine-amodiaquine combination (SP+AQ) - same doses as in SP and AQ, given simultaneously on day 0
Study: 2328557
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day fluoxetine
Study: 2328557
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day fluoxetine
Study: 25580087
Drug: Dobutamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine treatment to maintain StO2 ≥ 80%
Study: 25580087
Drug: Dobutamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine treatment
Study: 20386555
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment arm
Study: 20386555
Drug: Steroids before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids before study entry
Study: 18339790
Drug: Inhaled mannitol
Normalized name: mannitol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled mannitol (420 mg, twice daily for 2 weeks)
Study: 15975155
Drug: Glucose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (50 g carbohydrate drink)
Study: 15975155
Drug: Sucrose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (50 g carbohydrate drink)
Study: 6134626
Drug: Water (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (300 ml)
Study: 15975155
Drug: Fructose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (50 g carbohydrate drink)
Study: 8785133
Drug: morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.15 mg kg‐1 i.v. at peritoneal closure after hysterectomy (group post)
Study: 8785133
Drug: morphine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.15 mg kg‐1 on induction of anaesthesia (group pre‐low)
Study: 8785133
Drug: morphine 0.3
Normalized name: ethylmorphine 0.32 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.3 mg kg‐1 on induction of anaesthesia (group pre‐high)
Study: 8785133
Drug: morphine 0.3
Normalized name: ethylmorphine 0.32 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.3 mg kg‐1 i.v. on induction of anaesthesia (group pre‐high)
Study: 6387754
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment by their doctor (Control)
Study: 28415135
Drug: Enteral feeding
Normalized name: enteral feeding dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral feeding improvement massage (twice a day for 14 days)
Study: 26419096
Drug: ORS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS group (1,500 ml ORS 6 to 2 hours before anesthesia)
Study: 12012316
Drug: All‐trans retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: All‐trans retinoic acid (ATRA) and anthracycline‐based chemotherapy
Study: 10713869
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metoclopramide 150 micrograms kg‐1 and ondansetron 100 micrograms kg‐1
Study: 6384161
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sensitizers (misonidazole and hyperbaric oxygen)
Study: 30840831
Drug: Leucocyte-rich platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte-rich platelet-rich plasma (LR-PRP) injection
Study: 29763594
Drug: Intravenous Patient-Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Patient-Controlled Analgesia (PCA)
Study: 11288047
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (NA) 7.4 mg.kg(‐1) body weight before exercise and 3.7 mg.kg(‐1) at 0 and 30 minutes of exercise
Study: 9237962
Drug: Olestra 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra 0 g/d
Study: 9237962
Drug: Olestra 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra 8 g/d
Study: 9237962
Drug: Olestra 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra 20 g/d
Study: 9237962
Drug: Olestra 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra 32 g/d
Study: 2754630
Drug: Nortriptyline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline treatment
Study: 29948822
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg TNK‐tPA
Study: 29948822
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg TNK‐tPA
Study: 17228023
Drug: Adjuvant fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant fluorouracil (FU) treatment
Study: 7875113
Drug: Bilateral electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral electroconvulsive therapy (ECT)
Study: 7931862
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus Training and Employment Program (TEP)
Study: 7931862
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus TEP
Study: 2967089
Drug: Intravenous 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 7.5 mg dose of SQ 27, 519
Study: 2967089
Drug: Oral 10
Normalized name: Syringe Oral 10cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 10 mg doses of fosinopril sodium (capsule and solution)
Study: 2967089
Drug: Oral doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of fosinopril sodium
Study: 25944453
Drug: Rapid diagnosis
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid diagnosis and treatment of IS
Study: 25944453
Drug: Early diagnosis
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early diagnosis and treatment
Study: 20185602
Drug: QW dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: QW dosing of epoetin alfa
Study: 20185602
Drug: Q2W dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q2W dosing of epoetin alfa
Study: 20185602
Drug: Q4W dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q4W dosing of epoetin alfa
Study: 18237394
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (200,000 IU) plus zinc (10 mg elemental zinc, six days a week)
Study: 16730929
Drug: EPT (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPT (1 mg 17beta‐estradiol + 0.5 mg NETA)
Study: 14650366
Drug: nifuratel 125
Normalized name: nifuratel
DrugBank: Nifuratel (DB13724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifuratel 125 mg/nystatin 50000 IU
Study: 14650366
Drug: nifuratel 250
Normalized name: nifuratel 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifuratel 250 mg/nystatin 100000 IU
Study: 14650366
Drug: nifuratel 500
Normalized name: nifuratel
DrugBank: Nifuratel (DB13724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifuratel 500 mg/nystatin 200000 IU
Study: 10736141
Drug: Iontophoresis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis of a topical solution of 2% lidocaine with epinephrine 1:100,000
Study: 10736141
Drug: 2.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% lidocaine and 2.5% prilocaine (EMLA cream)
Study: 3157720
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline (NT) with cognitive therapy
Study: 29702652
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of H10407 at a dose of 105 CFU
Study: 29702652
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of H10407 at a dose of 106 CFU
Study: 23074170
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment at a dose of 0.1 IU/kg/day for 14 days
Study: 20567613
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic and steroids
Study: 8580280
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg q.d.s. for 1 week
Study: 8580280
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg t.d.s. for 1 week
Study: 31129370
Drug: Sequential multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential multiple assignment randomization trial (SMART) design
Study: 16739844
Drug: Governor Vessel
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Governor Vessel Daoqi needling method combined with antidepressants
Study: 16739844
Drug: Simple antidepressants
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple antidepressants
Study: 7640145
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan 100 mg
Study: 9051333
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference for injection
Study: 9051333
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral and subcutaneous sumatriptan
Study: 8377981
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 g single oral dose) for women and their partners
Study: 8377981
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 g single oral dose) for women
Study: 3803198
Drug: Oral tilidine
Normalized name: tilidine
DrugBank: Tilidine (DB13787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tilidine
Study: 3803198
Drug: Intramuscular tilidine
Normalized name: tilidine
DrugBank: Tilidine (DB13787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular tilidine
Study: 7485932
Drug: Parenteral morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral morphine
Study: 3384584
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 200 mg dl‐alpha‐tocopheryl acetate
Study: 28303587
Drug: AMX +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMX + 250 mg of MTZ for 14 days
Study: 28303587
Drug: AMX +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMX + 400 mg of MTZ for 14 days
Study: 28303587
Drug: 250 or
Normalized name: Urso-250 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 or 400 mg of MTZ for 7 days
Study: 26964159
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group (cetirizine)
Study: 21284065
Drug: Acceptance-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based behavioral therapy
Study: 19482866
Drug: Cladribine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine (5 mg/day for seven 5-day courses)
Study: 12740678
Drug: Aceclofenac 2
Normalized name: Aceclofenac 200 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac 2 x 100 mg daily
Study: 12740678
Drug: Diclofenac resinate
Normalized name: cholestyramine resin / diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac resinate 2 x 75 mg daily
Study: 10699617
Drug: Prolonged combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged combined androgen blockade (CAB) therapy (120 days or more)
Study: 10699617
Drug: Short-term combined
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term combined androgen blockade (CAB) therapy (less than 120 days)
Study: 10699617
Drug: Prolonged CAB
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged CAB therapy (120 days or more) in patients who lived at least 2 years
Study: 9328500
Drug: Acamprosate 1332
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 1332 mg/day
Study: 9328500
Drug: Acamprosate 1998
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 1998 mg/day
Study: 8229496
Drug: Bacterial polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial polysaccharide immune globulin (BPIG), 0.5 ml/kg, administered intramuscularly at entry and 30 days later.
Study: 8229496
Drug: Saline placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo, administered intramuscularly at entry and 30 days later.
Study: 29313180
Drug: Pasireotide subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide subcutaneous treatment (300–600 μg s.c. twice-daily)
Study: 29313180
Drug: Pasireotide long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide long-acting release (LAR) treatment (40–60 mg monthly)
Study: 29313180
Drug: Pasireotide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide treatment overall
Study: 24760537
Drug: Pasireotide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide treatment
Study: 26708314
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg aspirin daily for up to 24 weeks